SYHA1813

Customer Review

Based on 1 Customer Validation

SYHA1813 is a blood-brain barrier-penetrant, orally effective dual VEGFR and CSF1R receptor tyrosine kinase inhibitor. SYHA1813 exhibits IC50 values of 2.8, 0.3, 4.3, and 19.3 nM against VEGFR-1, VEGFR-2, VEGFR-3, and CSF1R, respectively. SYHA1813 blocks VEGFR and CSF1R kinase activity, inhibits pro-tumor macrophage polarization and angiogenesis, and modulates the tumor immune microenvironment. SYHA1813 activates the ATM/CHK/P53 signaling pathway, impairs DNA damage repair, and induces G2/M phase arrest, apoptosis, and senescence. SYHA1813 also inhibits c-Kit and PDGFRα kinases. SYHA1813 can be used for research on glioblastoma, malignant meningioma, melanoma, and diffuse large B-cell lymphoma.

For research use only. We do not sell to patients.

  • Purity : 99.46%
  • CAS No.: 1807466-30-3
  • Formula: C25H19FN4O
  • Molecular Weight:410.44
  • Storage:

    4°C, protect from light

    * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Protocols
  • Purity & Documentation
  • References
  • Help & FAQs
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00